amphetamine has been researched along with Alzheimer Disease in 11 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-dopa responsive parkinsonism could be an initial manifestation of Alzheimer's disease, which should be included in the differential diagnosis." | 5.40 | An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies. ( Hagiwara, M; Kasahata, N; Kato, H; Nakamura, A; Uchihara, T, 2014) |
| "L-dopa responsive parkinsonism could be an initial manifestation of Alzheimer's disease, which should be included in the differential diagnosis." | 1.40 | An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies. ( Hagiwara, M; Kasahata, N; Kato, H; Nakamura, A; Uchihara, T, 2014) |
| "Treatment with pimavanserin, a selective serotonin 5-HT(2A) receptor inverse agonist, prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches, reversed the augmented locomotor response to amphetamine, and normalized prepulse inhibition in mice with amyloid pathology." | 1.38 | Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. ( Bonhaus, DW; McFarland, K; Price, DL, 2012) |
| "Psychosis frequently occurs in Alzheimer's disease (AD), being associated with more severe cognitive decline, but the underlying mechanisms are unknown." | 1.32 | Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine. ( da Silva, AL; Dall'Igna, OP; Hoffmann, A; Lara, DR; Souza, DO, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Rochais, C | 1 |
| Lecoutey, C | 1 |
| Gaven, F | 1 |
| Giannoni, P | 1 |
| Hamidouche, K | 1 |
| Hedou, D | 1 |
| Dubost, E | 1 |
| Genest, D | 1 |
| Yahiaoui, S | 1 |
| Freret, T | 1 |
| Bouet, V | 1 |
| Dauphin, F | 1 |
| Sopkova de Oliveira Santos, J | 1 |
| Ballandonne, C | 1 |
| Corvaisier, S | 1 |
| Malzert-Fréon, A | 1 |
| Legay, R | 1 |
| Boulouard, M | 1 |
| Claeysen, S | 1 |
| Dallemagne, P | 1 |
| Lange, HS | 1 |
| Vardigan, JD | 1 |
| Cannon, CE | 1 |
| Puri, V | 1 |
| Henze, DA | 1 |
| Uslaner, JM | 1 |
| Kasahata, N | 1 |
| Hagiwara, M | 1 |
| Kato, H | 1 |
| Nakamura, A | 1 |
| Uchihara, T | 1 |
| Lapish, CC | 1 |
| Ahn, KC | 1 |
| Chambers, RA | 1 |
| Ashby, DM | 1 |
| Ahn, S | 1 |
| Phillips, AG | 1 |
| Gravius, A | 1 |
| Laszy, J | 1 |
| Pietraszek, M | 1 |
| Sághy, K | 1 |
| Nagel, J | 1 |
| Chambon, C | 1 |
| Wegener, N | 1 |
| Valastro, B | 1 |
| Danysz, W | 1 |
| Gyertyán, I | 1 |
| van Gaalen, MM | 1 |
| Relo, AL | 1 |
| Mueller, BK | 1 |
| Gross, G | 1 |
| Mezler, M | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| McFarland, K | 1 |
| Dall'Igna, OP | 1 |
| Hoffmann, A | 1 |
| da Silva, AL | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Carmona, P | 1 |
| Rodríguez-Casado, A | 1 |
| Alvarez, I | 1 |
| de Miguel, E | 1 |
| Toledano, A | 1 |
| Reisberg, B | 1 |
| Ferris, SH | 1 |
| Gershon, S | 1 |
| Siever, L | 1 |
| Kraemer, H | 1 |
| Sack, R | 1 |
| Angwin, P | 1 |
| Berger, P | 1 |
| Zarcone, V | 1 |
| Barchas, J | 1 |
| Brodie, HK | 1 |
1 review available for amphetamine and Alzheimer Disease
| Article | Year |
|---|---|
Pharmacotherapy of senile dementia.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Amphetamine; Antidepressive Agents, Tricyclic; Dementia | 1980 |
10 other studies available for amphetamine and Alzheimer Disease
| Article | Year |
|---|---|
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
Topics: Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Computer Simulation; Cryst | 2015 |
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.
Topics: Alzheimer Disease; Amphetamine; Animals; Association Learning; Behavior, Animal; Central Nervous Sys | 2021 |
An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies.
Topics: Aged, 80 and over; Alzheimer Disease; Amphetamine; Dementia; Humans; Imaging, Three-Dimensional; Lev | 2014 |
Selective effects of D- and L-govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia.
Topics: Alzheimer Disease; Amphetamine; Animals; Antipsychotic Agents; Avoidance Learning; Berberine Alkaloi | 2014 |
Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
Topics: Alzheimer Disease; Amphetamine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; F | 2011 |
NOGO-66 receptor deficient mice show slow acquisition of spatial memory task performance.
Topics: Alzheimer Disease; Amphetamine; Animals; Eating; Female; Fever; Hyperkinesis; Male; Maze Learning; M | 2012 |
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Topics: Alzheimer Disease; Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Disea | 2012 |
Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine.
Topics: Adenosine; Adrenergic Agents; Alzheimer Disease; Amphetamine; Amyloid beta-Peptides; Animals; Avoida | 2004 |
FTIR microspectroscopic analysis of the effects of certain drugs on oxidative stress and brain protein structure.
Topics: Alzheimer Disease; Amphetamine; Amyloid beta-Peptides; Animals; Brain; Brain Chemistry; Central Nerv | 2008 |
Gradients of biogenic amine metabolites in cerebrospinal fluid.
Topics: Alzheimer Disease; Amphetamine; Brain Diseases; Brain Neoplasms; Depression; Homovanillic Acid; Huma | 1975 |